Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fatal Cases of Bloodstream Infection by Fusarium solani and Review of Published Literature

  • 464 Accesses

  • 9 Citations

Abstract

Fusarium species are ubiquitously present in environment and are well known as human pathogens with high mortality rate in immunocompromised patients. We report here two cases where immunocompromised patients developed fatal bloodstream infections by this organism. Isolates were further identified by ITS1 region sequencing which confirmed them as Fusarium solani. Antifungal susceptibility testing was done following CLSI M38-A2 guidelines to amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and micafungin. Both patients had a fatal outcome and expired of septic shock. Therefore, identification up to species level is of utmost importance as that helps in directing the management of the patient thereby leading to a favourable outcome.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66:i5–i14.

  2. 2.

    Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55:809–18.

  3. 3.

    Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704.

  4. 4.

    Marie C, White TC. Genetic basis of antifungal drug resistance. Curr Fungal Infect Rep. 2009;3:163–9. doi:10.1007/s12281-009-0021-y.

  5. 5.

    Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24:247–80.

  6. 6.

    Healy M, Reece K, Walton D, Huong J, Frye S, Raad II, et al. Use of the Diversi Lab System for species and strain differentiation of Fusarium species isolates. J Clin Microbiol. 2005;43:5278–80.

  7. 7.

    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50:917–21.

  8. 8.

    Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol. 2002;40:3776–81.

  9. 9.

    Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother. 2002;46:3298–300.

  10. 10.

    Mseddi F, Jarboui MA, Sellami A, Sellami H, Ayadi A. A rapid and easy method for the DNA extraction from Cryptococcus neoformans. Biol Proced Online. 2011;21:13–5.

  11. 11.

    Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315–9.

  12. 12.

    Musa MO, Al Eisa A, Halim M, Sahovic E, Gyger M, Chaudhri N, et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol. 2000;108:544–8.

  13. 13.

    Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, Cavanna C, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol. 2012;50:1051–3.

  14. 14.

    Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398–403.

  15. 15.

    Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365–6.

  16. 16.

    Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41:4898–900.

  17. 17.

    Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2004;23:1059–61.

  18. 18.

    Rothe A, Seibold M, Hoppe T, Seifert H, Engert A, Caspar C, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394–7.

  19. 19.

    Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111–3.

  20. 20.

    Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine. 2011;90:69–80.

  21. 21.

    Ersal T, Al-Hatmi ASM, Cilo BD, Curfs-Breuker I, Meis JF, Özkalemkaş F, et al. Fatal disseminated infection with Fusarium petroliphilum. Mycopathologia. 2015;179:119–24.

  22. 22.

    Dananché C, Cassier P, Sautour M, Gautheron N, Wegrzyn J, Perraud M, et al. Fungaemia caused by Fusarium proliferatum in a patient without definite immunodeficiency. Mycopathologia. 2015;179:135–40.

  23. 23.

    de Souza M, Matsuzawa T, Lyra L, Busso-Lopes AF, Gonoi T, Schreiber AZ, et al. Fusarium napiforme systemic infection: case report with molecular characterization and antifungal susceptibility tests. Springerplus. 2014;3:492.

  24. 24.

    Kang Y, Li L, Zhu J, Zhao Y, Zhang Q. Identification of Fusarium from a patient with fungemia after multiple organ injury. Mycopathologia. 2013;176:151–5.

  25. 25.

    Esnakula AK, Summers I, Naab TJ. Fatal disseminated Fusarium infection in a human immunodeficiency virus positive patient. Case Rep Infect Dis. 2013;2013:379320. doi:10.1155/2013/379320.

  26. 26.

    Colombo A, Maccari G, Congiu T, Basso P, Baj A, Toniolo A. Colonization of a central venous catheter by the hyaline fungus Fusarium solani species complex: a case report and SEM imaging. Case Rep Med. 2013;2013:618358. doi:10.1155/2013/618358.

  27. 27.

    Fanci R, Pini G, Bartolesi AM, Pecile P. Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review. Rev Iberoam Micol. 2013;30:51–3. doi:10.1016/j.riam.2012.05.003.

  28. 28.

    Pereira GH, de Angelis DA, Brasil RA, dos Anjos Martins M, de Matos Castro e Silva D, Szeszs MW, et al. Disseminated amphotericin-resistant fusariosis in acute leukemia patients: report of two cases. Mycopathologia. 2013;175:107–14.

  29. 29.

    Schwartz KL, Sheffield H, Richardson SE, Sung L, Morris SK. Invasive fusariosis: a single pediatric center 15-year experience. J Pediatr Infect Dis Soc. 2013;. doi:10.1093/jpids/pit080.

  30. 30.

    O’Connell K, Kelehan J, Cormican M, Petrou MA, Hayat A, Keady D. Breakthrough Fusarium solani fungaemia in a patient with acute myeloid leukaemia receiving posaconazole prophylaxis after three days concomitant omeprazole. Int J Case Rep Image. 2011;2:7–12.

  31. 31.

    Jossi M, Ambrosioni J, Macedo-Vinas M, Garbino J. Invasive fusariosis with prolonged fungemia in a patient with acute lymphoblastic leukemia: case report and review of the literature. Int J Infect Dis. 2010;14:e354–6. doi:10.1016/j.ijid.2009.05.004.

  32. 32.

    Lodato F, Tamé MR, Montagnani M, Sambri V, Liguori G, Azzaroli F, et al. Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: an emerging fungal agent. Liver Transpl. 2006;12:1711–4.

  33. 33.

    Fang CT, Chang SC, Tang IL, Hsueh PR, Chang YL, Hung CC, et al. Fusarium solani fungemia in a bone marrow transplant recipient. J Formos Med Assoc. 1997;96:129–33.

Download references

Author information

Correspondence to Immaculata Xess.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dabas, Y., Bakhshi, S. & Xess, I. Fatal Cases of Bloodstream Infection by Fusarium solani and Review of Published Literature. Mycopathologia 181, 291–296 (2016). https://doi.org/10.1007/s11046-015-9960-8

Download citation

Keywords

  • Fusarium solani
  • Bloodstream infection
  • ITS1 DNA sequencing
  • Antifungal susceptibility testing
  • India